Targeted protein degraders: a call for collective action to advance safety assessment

被引：15

作者：

Jones, Lyn H. ^{[1
]}

Mitchell, Constance A. ^{[2
]}

Loberg, Lise ^{[3
]}

Pavkovic, Mira ^{[4
]}

Rao, Mohan ^{[5
]}

Roberts, Ruth ^{[6
,7
]}

Stamp, Katie ^{[8
]}

Volak, Laurie ^{[5
]}

Wittwer, Matthias B. ^{[9
]}

Pettit, Syril ^{[2
]}

机构：

[1] Dana Farber Canc Inst, Ctr Prot Degradat, Boston, MA 02115 USA

[2] Hlth & Environm Sci Inst, Washington, DC 17602 USA

[3] AbbVie, N Chicago, IL 60064 USA

[4] Bayer, Wuppertal, Germany

[5] Janssen Pharmaceut Companies Johnson & Johnson, San Diego, CA USA

[6] ApconiX, Alderley Edge, England

[7] Univ Birmingham, Dept Biosci, Birmingham, W Midlands, England

[8] Bristol Myers Squibb, New York, NY USA

[9] F Hoffmann La Roche, Roche Innovat Ctr Basel, Basel, Switzerland

来源：

NATURE REVIEWS DRUG DISCOVERY | 2022年 / 21卷 / 06期

关键词：

D O I：

10.1038/d41573-022-00055-9

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Targeted protein degraders (TPDs) are emerging classes of therapeutics that have the potential to address difficult drug targets in new ways. In 2021, experts convened to discuss challenges in TPD safety evaluation, and supported supplementing individual efforts to address these challenges with collective development of novel decision frameworks, tools and a shared evidence base. Targeted protein degraders (TPDs) are emerging classes of therapeutics that have the potential to address difficult drug targets in new ways. In 2021, experts convened to discuss challenges in TPD safety evaluation, and supported supplementing individual efforts to address these challenges with collective development of novel decision frameworks, tools and a shared evidence base.

引用

页码：401 / 402

页数：2

共 50 条

[21] Fundamental aspects of DMPK optimization of targeted protein degraders [J].

Cantrill, Carina ;

Chaturvedi, Prasoon ;

Rynn, Caroline ;

Schaffland, Jeannine Petrig ;

Walter, Isabelle ;

Wittwer, Matthias B. .

DRUG DISCOVERY TODAY, 2020, 25 (06) :969-982

[22] Macrocyclic peptides as a new class of targeted protein degraders [J].

Jing, Xuefei ;

Mackay, Joel P. ;

Passioura, Toby .

RSC CHEMICAL BIOLOGY, 2025, 6 (03) :326-337

[23] A Cross-Pharma Benchmark of the Current Preclinical Safety Assessment Practices to Support Development of Targeted Protein Degraders: Results from an IQ Survey [J].

Stamp, Katie ;

Hemkens, Michelle ;

Loberg, Lise ;

Moreau, Kevin ;

Zane, Doris ;

Hart, Tim .

INTERNATIONAL JOURNAL OF TOXICOLOGY, 2023, 42 (01) :101-101

[24] Road safety: A call for action [J].

Omar, A. H. ;

Ashawesh, K. .

LIBYAN JOURNAL OF MEDICINE, 2008, 3 (03) :126-127

[25] Collective action in SCM: a call for activist research [J].

Touboulic, Anne ;

McCarthy, Lucy .

INTERNATIONAL JOURNAL OF LOGISTICS MANAGEMENT, 2020, 31 (01) :3-20

[26] Recent advances in targeted protein degraders as potential therapeutic agents [J].

Na Yang ;

Bo Kong ;

Zhaohong Zhu ;

Fei Huang ;

Liliang Zhang ;

Tao Lu ;

Yadong Chen ;

Yanmin Zhang ;

Yulei Jiang .

Molecular Diversity, 2024, 28 :309-333

[27] PROTAC™ targeted protein degraders: Exciting modality for drug discovery [J].

Araujo, Erika .

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 258

[28] A call to action: the compelling need to advance the role of urgency [J].

Staskin, David R. .

WORLD JOURNAL OF UROLOGY, 2009, 27 (06) :765-766

[29] Industry perspective on the nonclinical safety assessment of heterobifunctional degraders [J].

Hemkens, Michelle ;

Stamp, Katie ;

Loberg, Lise I. ;

Moreau, Kevin ;

Hart, Tim .

DRUG DISCOVERY TODAY, 2023, 28 (08)

[30] Targeted protein degraders march towards the clinic for neurodegenerative diseases [J].

Hassan, Md. Imtaiyaz ;

Kumar, Dhiraj .

AGEING RESEARCH REVIEWS, 2022, 78

← 1 2 3 4 5 →